The IDH mutation is critical for diagnosis, treatment efficacy evaluation, survival prediction, and reduced invasiveness of biomarkers associated with glioma, and is widely deemed the most significant genetic alteration (13, 14). This evidence concerns the gene IDH1 and glioma.